Emcure Pharmaceuticals | Business Upturn

Emcure appoints C S Muralidharan as independent director for three-year term

Arunika Jain — Mon, 27 Apr 2026 14:53:08 +0000

Emcure Pharmaceuticals has announced the appointment of Mr. C S Muralidharan as an Independent Director for a three-year term starting from April 1, 2026. The decision was approved by the company’s members through a Postal Ballot conducted via remote e-voting.

The company confirmed that Mr. Muralidharan is not restricted from serving as a director by any Securities and Exchange Board of India (SEBI) order, and he is not related to any current directors or key managerial personnel of Emcure Pharmaceuticals. This compliance is in line with BSE and NSE circulars dated June 20, 2018.

The e-voting process for the Postal Ballot concluded on April 24, 2026, at 5:00 p.m. IST. The results of the ballot were announced on April 27, 2026, following the receipt of the Scrutinizer’s report.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Emcure Pharmaceuticals reduces Poviztra starting dose price by 55%

Kinjal — Thu, 02 Apr 2026 09:53:51 +0000

Emcure Pharmaceuticals Ltd. has announced a significant reduction in the price of its weight management drug, Poviztra® (semaglutide injection), across India. The starting dose price has been slashed by 55%, making it available at ₹999 per week or ₹3,999 per month, inclusive of taxes. This move is aimed at expanding patient access to the drug.

The company has revised the prices of Poviztra® by an average of 47% across all doses. The drug, which is available in a once-weekly pen device, comes in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg. The revised pricing will take effect from April 3, 2026.

Emcure Pharmaceuticals is the first Indian company to exclusively distribute and commercialise Poviztra®, a second brand of Novo Nordisk’s semaglutide injection for obesity. The price revision is expected to make the innovator molecule, which is backed by robust clinical and real-world evidence, accessible to a significantly larger patient base in India.

The old and revised monthly prices for Poviztra® are as follows:
– Poviztra® 0.25 mg: ₹8,790 reduced to ₹3,999
– Poviztra® 0.5 mg: ₹11,200 reduced to ₹4,999
– Poviztra® 1 mg: ₹11,200 reduced to ₹5,999
– Poviztra® 1.7 mg: ₹13,000 reduced to ₹7,999
– Poviztra® 2.4 mg: ₹15,000 reduced to ₹8,999

Satish Mehta, CEO and Managing Director of Emcure Pharma, stated, “The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity. Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale.”

Obesity is linked to over 230 health complications, including cardiovascular disease, type 2 diabetes, hypertension, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease, and Alzheimer’s disease. With this price reduction, Emcure Pharma reinforces its commitment to advancing patient access, improving health outcomes, and supporting innovative treatments that address the growing burden of obesity in India.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Emcure Pharmaceuticals acquires Cutimed Inc. for CAD $5.05 million

Yash Agarwal — Wed, 01 Apr 2026 16:16:18 +0000

Emcure Pharmaceuticals has announced the acquisition of Cutimed Inc., a Canadian company specialising in cosmetics and personal care products. The acquisition, valued at up to CAD $5.05 million, was executed through Emcure’s step-down subsidiary, Mantra Pharma Inc., which is a subsidiary of Marcan Pharmaceuticals Inc. This strategic move aligns with Emcure’s long-term growth strategy to enhance its presence in the Canadian dermatological and cosmetic product segments.

Cutimed Inc., incorporated in Québec, Canada, has been operational since 2011, focusing on the development and commercialisation of cosmetic and dermatological products, including creams, cleansers, and lip care products. The company reported an annual turnover of CAD $2.8 million, primarily from the Canadian market.

The acquisition does not constitute a related party transaction, as neither the promoter, promoter group, nor group companies of Emcure had any prior interest in Cutimed. The acquisition and subsequent amalgamation with Mantra Pharma Inc. are expected to strengthen Emcure’s portfolio in the Canadian market and support its long-term growth strategy.

Following the acquisition, Cutimed has been amalgamated with Mantra Pharma Inc. effective April 01, 2026, using the short-form amalgamation procedure under the Business Corporations Act (Québec). This amalgamation aims to consolidate Emcure’s Canadian operations and achieve operational and administrative efficiencies.

The acquisition was completed with cash consideration, and no government approvals were required beyond customary conditions and compliance with applicable Canadian laws. Emcure’s acquisition of Cutimed is a strategic step to bolster its presence in the pharmaceuticals and healthcare industry, particularly in the Canadian market.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Emcure announces re-appointment of independent directors for second terms

Arunika Jain — Tue, 24 Mar 2026 08:41:27 +0000

Emcure Pharmaceuticals has announced the re-appointment of three independent directors for second terms, following approval from the company’s members through a postal ballot and remote e-voting process. The re-appointments include Mr. Vijay Keshav Gokhale, Dr. Vidya Rajiv Yeravdekar, and Dr. Shailesh Kripalu Ayyangar.

Mr. Vijay Keshav Gokhale will serve a second term of five consecutive years starting from 16 April 2026. Dr. Vidya Rajiv Yeravdekar has been re-appointed for a second term of three consecutive years, also beginning on 16 April 2026. Dr. Shailesh Kripalu Ayyangar will continue for another five-year term, effective from 2 June 2026.

The company confirmed that all three directors are not debarred from holding office by any Securities and Exchange Board of India (SEBI) order or any other authority. Additionally, they are not related to any directors or key managerial personnel of Emcure Pharmaceuticals.

The remote e-voting process concluded at 5:00 p.m. IST on 20 March 2026, and the results of the postal ballot were announced on 24 March 2026, following the receipt of the scrutiniser’s report dated 23 March 2026.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Emcure Pharmaceuticals Q3 Results: Revenue jumps 20.4% YoY to Rs 2,363 crore, net profit up 50%

Aman Shukla — Wed, 04 Feb 2026 08:08:10 +0000

Emcure Pharma delivered a strong performance in Q3, posting healthy growth across key financial metrics and highlighting steady execution despite a competitive pharma environment.

The company’s net profit surged 50% year-on-year to ₹230.5 crore, compared with ₹154 crore in the same quarter last year. This sharp jump reflects improved operating leverage and better cost efficiencies during the quarter.

On the topline front, revenue rose 20.4% YoY to ₹2,363 crore, up from ₹1,962 crore, supported by steady momentum across core therapeutic segments and continued traction in domestic as well as select international markets.

Operating performance also remained robust. EBITDA climbed 39% YoY to ₹493 crore, compared with ₹355 crore a year ago, while EBITDA margins expanded to 20.8% from 18%, indicating stronger profitability and disciplined expense management.

At the market level, Emcure Pharma shares were trading at ₹1,537.00, up ₹30.80 or 2.04%, reflecting a positive investor response following the strong Q3 performance.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Emcure Pharmaceuticals partners with Novo Nordisk India to launch Poviztra (Semaglutide 2.4 mg) for weight management

Aman Shukla — Mon, 10 Nov 2025 05:57:28 +0000

Emcure Pharmaceuticals Ltd and Novo Nordisk India today announced a strategic partnership to launch Poviztra® (semaglutide injection 2.4 mg) in India. This collaboration marks a significant step towards expanding access to advanced weight management solutions across the country.

Under this partnership, Emcure Pharma will serve as the exclusive distributor responsible for the commercialisation and marketing of Poviztra®, ensuring the product reaches a wider patient population, particularly in regions beyond Novo Nordisk India’s existing network.

Poviztra® is the second brand of Wegovy®, Novo Nordisk’s globally recognized semaglutide injection 2.4 mg, which was launched in India in June 2025. Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management and for reducing the risk of major adverse cardiovascular events in individuals with overweight or obesity.

Clinical studies have shown that 1 in 3 participants using Wegovy® experienced over 20% weight loss, making semaglutide one of the most effective pharmacological treatments for obesity management available today.

With Poviztra®, Novo Nordisk India aims to broaden access to its innovative obesity therapy and meet the growing demand for safe and effective weight-loss medications in India.

Semaglutide 2.4 mg (Wegovy®/Poviztra®) is backed by strong clinical evidence from multiple global obesity trials conducted under the STEP and SELECT programmes. The molecule has been on the market for nearly a decade, with 38 million patient-years of exposure, supported by extensive real-world evidence and clinical safety data.

Emcure Pharmaceuticals Gujarat plant clears USFDA inspection with zero observations

Aman Shukla — Fri, 10 Oct 2025 08:21:07 +0000

Emcure Pharmaceuticals Limited has announced that its manufacturing facility located at Kadu in Surendranagar district, Gujarat, has successfully cleared a surveillance inspection conducted by the United States Food and Drug Administration (USFDA).

The inspection, which took place from October 6 to October 10, 2025, concluded without any observations, indicating full compliance with the USFDA’s quality and regulatory standards.

This development reinforces Emcure’s strong focus on maintaining high manufacturing standards and global quality benchmarks. A clean USFDA report not only enhances the company’s credibility in the international pharmaceutical market but also supports its ongoing growth in regulated markets like the United States.

Emcure Pharmaceuticals shares jump 5% as Q4 profit rises 63% YoY to Rs 197.2 crore

Aman Shukla — Thu, 22 May 2025 09:22:06 +0000

Emcure Pharmaceuticals shares surged 4% after the company reported robust Q4 FY25 earnings. As of 2:50 PM, the shares were trading 4.70% higher at Rs 1,124.10.

For the quarter ended March 31, 2025, Emcure posted a 63% year-on-year (YoY) jump in net profit at ₹197.2 crore, compared to ₹121 crore in Q4 FY24. Revenue from operations rose 19.4% YoY to ₹2,116.2 crore, up from ₹1,771.4 crore in the same period last year.

EBITDA grew 29.7% to ₹402 crore, with the EBITDA margin expanding to 19.01% from 17.5%, reflecting improved efficiency and cost control. Total income came in at ₹2,120.7 crore, while expenses rose to ₹1,849.7 crore, largely due to higher procurement and employee costs.

For the full financial year FY25, Emcure reported revenue of ₹7,896 crore, up from ₹6,658 crore in FY24. Net profit rose 34% YoY to ₹707.4 crore from ₹527.6 crore last year.

The company credited its performance to strong growth in domestic and international markets, a better product mix, and strategic investments in R&D and new product launches.

Emcure Pharmaceuticals receives EIR from USFDA with VAI classification for Kurkumbh API facility

Aman Shukla — Fri, 18 Apr 2025 11:43:34 +0000

Emcure Pharmaceuticals has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) manufacturing facility located in Kurkumbh, Taluka – Daund, Pune, Maharashtra.

The inspection, which was previously communicated by the company on February 26, 2025, has been classified by the USFDA as “Voluntary Action Indicated” (VAI). This classification indicates that the facility may have some objectionable conditions or practices, but regulatory action is not currently being recommended. The company is expected to take voluntary corrective actions to address the issues identified.

The Kurkumbh facility is a key part of Emcure’s API manufacturing operations. Receipt of the EIR and the VAI status suggests that while the facility remains operational, it will need to implement improvements in line with regulatory expectations.

Emcure Pharmaceuticals receives two observations for its Kurkumbh facility from US FDA after cGMP inspection

Aman Shukla — Wed, 26 Feb 2025 06:28:54 +0000

Emcure Pharmaceuticals, a leading global pharmaceutical company, recently underwent a current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (US FDA) at its Active Pharmaceutical Ingredient (API) manufacturing facility in Kurkumbh, Pune. The inspection was conducted from February 19, 2025, to February 25, 2025.

At the conclusion of the inspection, the company received two observations in Form 483. These observations indicate areas where the FDA believes improvements are necessary to meet regulatory compliance standards.

In the exchange filing, the company shared, “The United States Food and Drug Administration (“US FDA”) had conducted a current Good Manufacturing Practices (‘cGMP’) inspection of Company’s API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka – Daund, Pune – 413802, Maharashtra, from February 19, 2025 to February 25, 2025. On conclusion of the inspection, the Company received two observations in Form 483.”

Emcure Pharmaceuticals is fully committed to maintaining the highest quality and regulatory standards. The company is actively addressing the observations and will provide a comprehensive response to the US FDA within the stipulated timeframe.

Emcure Pharmaceuticals Q3 FY25 Results: Revenue up 18% YoY to Rs 1963 crore, Net Profit up 30% YoY

Aditya Bhagchandani — Thu, 06 Feb 2025 09:29:07 +0000

Emcure Pharmaceuticals Ltd. (BSE: 544210, NSE: EMCURE) announced impressive financial results for Q3 FY25, showcasing strong growth across revenue and profitability metrics, led by robust international sales and effective cost management.

Key Highlights:

Revenue from operations: ₹1,963 crore, up 17.7% YoY from ₹1,668 crore
EBITDA: ₹362 crore, a 23.2% YoY increase from ₹294 crore
EBITDA Margin: 18.4% versus 17.6% YoY
Profit After Tax (PAT): ₹156 crore, up 30.3% YoY from ₹120 crore
Domestic business sales: ₹888 crore, a 12% YoY increase
International business sales: ₹1,075 crore, up 23% YoY

Detailed Performance:
Emcure’s domestic business contributed ₹888 crore to the topline, driven by a stable base business and in-licensed products. Meanwhile, its international operations recorded a 23% YoY growth at ₹1,075 crore, with robust performance in Rest of the World (RoW) markets, particularly with a 40% YoY surge in key regions like Canada and the EU.

The company saw its EBITDA margins expand to 18.4% due to operational efficiencies, despite a slight drop in gross profit margins to 60.1% from 62.7% in Q3 FY24, reflecting increased material costs.

Segment-wise Revenue Growth (YoY):

Domestic: ₹888 crore (+12%)
Rest of the World (RoW): ₹365 crore (+40%)
EU: ₹358 crore (+1.9%)
Canada & Others: ₹352 crore (+33.8%)

Management Commentary:
Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, commented, “We are witnessing strong growth across international markets, underpinned by our differentiated product portfolio. Our focus on new product launches and synergies with in-licensed products continues to drive growth and enhance margins.”

With expanding demand across international markets and an increasing product base, Emcure is on track to sustain its growth momentum and improve margins further.

Emcure Pharmaceuticals shares jump 4% – Here’s why

Aman Shukla — Mon, 11 Nov 2024 05:34:48 +0000

Emcure Pharmaceuticals saw a significant 4% rise in its share price following impressive Q2 2024 earnings.

The company’s net profit surged by 39.83%, reaching ₹194.57 crore compared to ₹139.15 crore in Q2 2023. Additionally, Emcure reported a 20.38% increase in sales, totalling ₹2001.98 crores, up from ₹1663.09 crores in the same period last year.

As of 11:06 am, Emcure Pharmaceuticals shares were trading 4.46% higher at Rs 1,455.95 on the NSE.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Emcure Pharmaceuticals stock jumps over 4% after strong Q2 results

Aman Shukla — Fri, 08 Nov 2024 03:54:18 +0000

Emcure Pharmaceuticals shares surged by over 4% in early trading following impressive Q2 earnings for the quarter ending September 2024.

The company reported a 39.83% increase in net profit, reaching Rs 194.57 crore compared to Rs 139.15 crore in Q2 2023. Emcure also saw a 20.38% boost in sales, totalling Rs 2001.98 crore, up from Rs 1663.09 crore in the same period last year.

As of 9:23 am, Emcure Pharmaceuticals shares were trading 3.02% higher at Rs 1,483.35 on the NSE.

Emcure Pharmaceuticals launches Emcutix Biopharmaceuticals to expand dermatology portfolio

Aman Shukla — Mon, 28 Oct 2024 12:51:48 +0000

Emcure Pharmaceuticals Limited, a prominent player in the Indian pharmaceutical sector, is aiming to cater to a growing dermatology segment in India by forming a wholly-owned subsidiary, Emcutix Biopharmaceuticals Limited. This strategic move aims to enhance Emcure’s existing dermatology operations and meet the growing demands of the Indian market.

The focus will be on building a differentiated product portfolio, including first-time launches targeted to meet the unmet requirements of the Indian dermatology market.

With a dedicated team and a renewed focus, Emcutix is set to develop a diverse range of innovative products tailored to address the unmet needs of Indian consumers. The Indian dermatology market, valued at $1.84 billion as of July 2024 according to IQVIA, is experiencing significant growth driven by an expanding population and increasing consumer awareness about skin health.

Emcure Pharmaceuticals signs licensing agreement with Gilead for manufacture and supply of Lenacapavir

Aman Shukla — Thu, 03 Oct 2024 04:51:08 +0000

Emcure Pharmaceuticals has recently informed exchanges that the company signed a royalty-free licensing agreement with Gilead Sciences to manufacture and supply generic versions of lenacapavir for HIV prevention and treatment in 120 countries, especially in low- and lower-middle-income regions.

The partnership will ensure the availability of affordable lenacapavir and highlights Emcure’s dedication to innovative global healthcare.

Managing Director and CEO, Emcure Pharmaceuticals Ltd., stated, “We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines. As the leader in HIV antiviral segment in covered market in India with long standing experience in supplying HIV medicines to over 100 LMIC countries, Emcure is uniquely positioned to drive impactful change in the global fight against HIV. By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide.”